Replimune

18 Commerce Way
Woburn
Massachusetts
01801
United States

Email: info@replimune.com

Show jobs for this employer

About Replimune

Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune intends to progress these rapidly through clinical trials and to combine these with checkpoint blockade at an early stage of clinical development.

YEAR FOUNDED:
April 2015

LEADERSHIP:
Executive Chairman & Director: Philip Astley-Sparke
CEO & Director: Robert Coffin, Ph.D.
COO: Colin Love, Ph.D.
CBO: Pamela Esposito, Ph.D.
CMO: Howard Kaufman, M.D.
VP, Clinical Development: Susan Doleman
Sr. VP of Regulatory Affairs and QA: Anne Marie Woodland
VP, Research: Suzanne Thomas, Ph.D.

SCIENCE:
Please click here for Replimune's science.

5 articles with Replimune